BioPharmSignal logoBioPharmSignal

Biotech News

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

SCYNEXIS (SCYX)SCYNEXISCompany update

SCYX (SCYX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is scyx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYXSCYNEXIS2026-09-28 11:30 EST

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

MBRXMoleculin Biotech, Inc.2026-05-21 21:02 EST

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

IMNNImunon2026-08-26 12:30 EST

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

MBRXMoleculin Biotech, Inc.2026-09-14 12:35 EST

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

IMNNImunon2026-09-09 12:30 EST

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

SCYNEXIS

Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression. Antifungal Franchise SCY-247 is...

Recent company news

SCYXSCYNEXIS2026-11-05 13:20 EST

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-10-29 12:00 EST

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYXSCYNEXIS2026-10-21 20:05 EST

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Stock data

Close
3.30 USD
Market cap
50.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States